

# Monday 17th June

8:00 - 9:00	<b>Registration</b> <b>(Pre-Conference session: Introduction for students and new starters)</b>			
9:00 – 9:30	<b>Conference Opening Remarks</b>			
9:30 – 10:30	<b>Biostatistics in a post-pandemic era: lessons learned for research, public health, drug and vaccine development, policy advice, and communication</b>  <b>Geert Molenberghs</b>  <b>Room: Effectenbeurszaal</b>			
10:30 – 11:00	<b>Break</b>			
11:00 – 12:30	<b>Estimands for time-to-event outcomes: re-thinking old questions within the Estimand framework</b>	<b>Biomarkers ESIG: Advancing Biomarker Insights in Precision Medicine and Digital Health</b>	<b>Patient Focused Drug Development (PFDD) SIG: Hot Topics</b>	<b>Project Leadership Interactive Workshop</b>
	Looking back on our oncology estimand SIG working group journey <b>Evgeny Degtyarev &amp; Kaspar Rufibach</b>	Machine Learning as an enabler of precision medicine <b>Nils Ternès (Sanofi), Karl Köchert (Bayer)</b>	Introduction of the new PFDD SIG <b>Rachael Lawrance</b>	This interactive workshop focuses on the skills needed to successfully plan and execute a project. Attendees will look at different scenarios during an example project and explore approaches such as:- Understanding scope, responsibilities and expectations – Communication and planning with other functional leads – Leading the team to deliver and monitoring progress- Building a relationship with customers or stakeholders – Mitigating risk and problem solving.
	Re-Thinking treatment effect measure in clinical trials with time-to-event outcomes and competing risks <b>Tobias Mütze &amp; Stefan Englert</b>		Setting meaningful PRO objectives in oncology clinical trials <b>Konstantina Skaltsa</b>	

	<p>Outcome and learnings from a recent survey on current practice in covariate adjustment and stratified analysis <b>Sarwar I. Mozumder</b></p>	<p>Digital biomarkers: the essential guide for statisticians. <b>Marzia A. Scelsi (Roche)</b></p>	<p>Emerging Patient-Centric Tolerability Endpoints <b>John Devin Peipert</b></p>	<p><b>Vicky Marriott, Kimberley Hacquoil, Naomi Givens</b></p>
	<p>Can we improve the analysis of safety events of special interest using the Estimand Framework? <b>Pedro Lopez-Romero</b></p>	<p>Panel discussion <b>Gaëlle Saint-Hilary (Saryga), Juan José Abellan (EMA), Kostas Sechidis (Novartis), Marzia Scelsi (Roche)</b></p>	<p>Digital endpoints opportunities and challenges <b>Alexandra Lauer</b></p>	
12:30 – 13:30	<p style="text-align: center;"><b>Lunch</b> <b>(Join Lizzi Pitt in the Career Young Networking Session)</b></p>			
13:30 – 15:00	<p><b>How to Generate Evidence from Real World Data</b></p>	<p><b>Causal Inference &amp; Estimand</b></p>	<p><b>Basket trials and personalised medicine</b></p>	<p><b>Level up your career: How coaching and mentoring can help you take the next step</b></p>
	<p>Workflow for generating evidence from RWD <b>Rima Izem (Novartis)</b></p>	<p>Targeted Maximum Likelihood Estimation; Do we have a free lunch? <b>Bob Murray</b></p>	<p>Adding baskets to an ongoing basket trial with information borrowing: When do you benefit? <b>Libby Daniells</b></p> <p>When should we borrow across disease populations in a basket trial? <b>Elizabeth Pilling</b></p>	<p>In this interactive workshop, Participants will learn about mentoring and coaching the differences between them and how they can be used effectively to progress your career. Hear from peers in the industry on how they have used coaching and mentoring in their careers as well as a demonstration of a typical session between certified coaches. In order to get the most from</p>

	The workflow in practice: an External Control Arm Case Study <b>Min-Hua Jen (Lilly)</b>	Estimand in Formulation Studies: Insight from IMscin trials <b>Mahesh Shivhare</b>	Clustering methods for frequentist adaptive basket trials <b>Michaela Maria Freitag</b>	the session, participants will be expected to bring their own situations to discuss in groups with feedback from the coaches. <b>Xinyi Zhu, Alun Bedding, Lucy Rowell</b>
	Panel discussion <b>Josie Wolfram (Astellas) and Kit Roes</b>	Estimand and Complex Innovative Designs <b>Olivier Collignon</b>	Heterogeneity in treatment effects: random or real? <b>Thomas Jaki</b>	
		Addressing Administrative Withdrawals in Clinical Trials in Estimation under the Treatment Policy Strategy <b>Yongming Qu</b>		
15:00 – 15:15	<b>Changeover</b>			
15:15 – 16:30	<b>Career Young Session 2</b>	<b>Data Visualization and animation</b>	<b>HTA</b>	<b>Interactive session on Data Monitoring Committees</b>
	Enhancing Variable Importance Interpretation in Machine Learning with Conditional Permutation Importance <b>Ahmad Chamma</b>	How To Draw A Really Bad Graph <b>Chris Harbron</b>	Enhanced subgroup identification in heterogeneous clinical courses of disease burden using a machine learning score from CT images. <b>Grace Hyun Kim</b>	While DMCs are widely used considerable variability exists in conduct. This interactive session will focus on three topics: open sessions and open reports; communication pathways within and between the various parties involved with DMCs (i.e. the DMC themselves, the sponsor or academic clinical trials unit, and the independent statistical reporting group/CRO); and non-standard DMCs (e.g. adaptive designs).
	Patterns of repeat non-fatal events and death in heart failure trials: implications for improving future research. <b>Audinga-Dea Hazewinkel</b>	Statistics - made accessible <b>Ursula Becker</b>	Developing Trial-Based Risk Prediction Models: At the Intersection of Clinical Opinion and Data-driven Insights <b>Milana Ivkovic, Martin Bøg</b>	

	R(ise) & Shiny: Taking steps to utilise R packages in Shiny applications <b>Emily Foreman</b>	Data story telling <b>Bodo Kirsch</b>	Open-source workflows for HTA: insights and implications from a pharma industry survey <b>Rossella Belleli (Roche), Amelie Elsässer (Boehringer Ingelheim), Nermina Ferizovic (University College London), Anders Gorst-Rasmussen (Novo Nordisk)</b>	
	<i>Recruitment-informed Bayesian Analysis of Vaccine Efficacy</i> <b>Marco Ratta</b>		QTwIST and shout: Censoring and choice of Tau in Quality Adjusted Time Without Symptoms of Toxicity. <b>Saiful Islam</b>	
16:30 – 17:00	<b>Break</b>			
17:00 – 18:00	<b>Po: Gone in 60 seconds: 1 Minute Poster Previews</b>			
18:00 – 19:00	<b>Poster Session</b>			
19:00 – 20:00	<b>Free Time</b>			
20:00 – 22:00	<b>Social Event</b>			